These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 17329198)
1. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M Lancet Oncol; 2007 Mar; 8(3):273-4. PubMed ID: 17329198 [No Abstract] [Full Text] [Related]
2. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254 [No Abstract] [Full Text] [Related]
3. Dasatinib in chronic myelogenous leukemia. Chu SC; Tang JL; Li CC N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978 [No Abstract] [Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
5. Dasatinib is effective in imatinib-resistant CML. Cannell E Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950 [No Abstract] [Full Text] [Related]
6. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. Abbott BL Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209 [TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib. Martin SE; Sausen M; Joseph A; Kingham BF Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399 [No Abstract] [Full Text] [Related]
9. [Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?]. Gómez Casares MT; León LG Med Clin (Barc); 2013 Aug; 141(3):111-3. PubMed ID: 23462544 [No Abstract] [Full Text] [Related]
10. Management of Bcr-Abl-positive leukemias with dasatinib. Hochhaus A Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922 [TBL] [Abstract][Full Text] [Related]
11. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110 [No Abstract] [Full Text] [Related]